Yttrium 90 Ibritumomab Tiuxetan use while Breastfeeding
Medically reviewed by Drugs.com. Last updated on Apr 28, 2024.
Yttrium 90 Ibritumomab Tiuxetan Levels and Effects while Breastfeeding
Summary of Use during Lactation
Information in this record refers to the use of yttrium 90 ibritumomab tiuxetan as a therapeutic agent. No information is available on the use of yttrium 90 ibritumomab tiuxetan during breastfeeding. Because of the long half-life of yttrium 90, the manufacturer and expert opinion recommend not administering the drug in women who wish to continue breastfeeding.[1] If the drug is administered to a nursing mother, breastfeeding should be discontinued. No restrictions on holding the infant after administration of the drug are necessary.[2]
Drug Levels
Yttrium-90 decays by emission of beta particles, with a physical half-life of 64.1 hours and a decay energy of 2.28 MeV.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
- 1.
-
Goldsmith SJ. Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med 2010;40:122-35. [PubMed: 20113680]
- 2.
-
Gulec SA, Siegel JA. Posttherapy radiation safety considerations in radiomicrosphere treatment with 90Y-microspheres. J Nucl Med 2007;48:2080-6. [PubMed: 18006608]
Substance Identification
Substance Name
Yttrium 90 Ibritumomab Tiuxetan
CAS Registry Number
1460293-15-5
Drug Class
Breast Feeding
Lactation
Milk, Human
Radiopharmaceuticals
Yttrium Radioisotopes
-
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- Drug Levels and Effects
- Substance Identification
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.